Holen Sie sich die Stockscreener-App
70.61
0.19%
0.15
Schlusskurs vom Vortag:
$70.76
Offen:
$70.63
24-Stunden-Volumen:
81,610
Relative Volume:
0.27
Marktkapitalisierung:
$1.49B
Einnahmen:
$486.82M
Nettoeinkommen (Verlust:
$18.78M
KGV:
86.11
EPS:
0.82
Netto-Cashflow:
$100.45M
1W Leistung:
+3.70%
1M Leistung:
+4.86%
6M Leistung:
+21.17%
1J Leistung:
+7.42%
1-Tages-Spanne:
$69.29
$71.16
1-Wochen-Bereich:
$68.19
$72.57
52-Wochen-Spanne:
$52.50
$72.57
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Firmenname
Ani Pharmaceuticals Inc
Sektor
Telefon
(218) 634-3500
Adresse
210 MAIN STREET WEST, BAUDETTE, MN
Vergleichen Sie ANIP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
70.60 | 1.49B | 486.82M | 18.78M | 100.45M | 0.82 |
|
ZTS
Zoetis Inc
|
155.29 | 66.90B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.28 | 48.25B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.16 | 47.13B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.38 | 16.06B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
297.64 | 13.15B | 2.76B | 1.11B | 898.10M | 22.77 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-14 | Eingeleitet | Jefferies | Buy |
| 2025-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2024-12-11 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-15 | Eingeleitet | CapitalOne | Overweight |
| 2023-08-22 | Bestätigt | H.C. Wainwright | Buy |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-02 | Eingeleitet | Truist | Buy |
| 2020-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-05-10 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | Bestätigt | Canaccord Genuity | Buy |
| 2017-07-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-02-22 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-06-23 | Eingeleitet | Raymond James | Strong Buy |
| 2016-05-24 | Herabstufung | Standpoint Research | Buy → Hold |
| 2015-11-13 | Eingeleitet | Standpoint Research | Buy |
| 2015-09-28 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2015-08-05 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-04 | Bestätigt | ROTH Capital | Neutral |
| 2015-07-31 | Bestätigt | Oppenheimer | Outperform |
| 2015-07-15 | Bestätigt | ROTH Capital | Neutral |
| 2015-06-23 | Bestätigt | Oppenheimer | Outperform |
| 2015-05-18 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Bestätigt | Oppenheimer | Outperform |
| 2015-04-10 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-02-26 | Bestätigt | ROTH Capital | Buy |
| 2015-02-18 | Bestätigt | Oppenheimer | Outperform |
Alle ansehen
Ani Pharmaceuticals Inc Aktie (ANIP) Neueste Nachrichten
The 4.0% return this week takes ANI Pharmaceuticals' (NASDAQ:ANIP) shareholders three-year gains to 135% - simplywall.st
Press Release Distribution & PR Platform - ACCESS Newswire
Zacks.com featured highlights include Heritage Insurance, Marex, Kingstone, ANI Pharmaceuticals and HCI - TradingView
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year? - Yahoo Finance
Zacks.com featured highlights include ANI Pharmaceuticals, Heritage Insurance, Avista and Exelon - Yahoo Finance
Buy 4 Low-Beta Stocks ANIP, LRN, MASS & CTGO as Tariff Woes Continue - TradingView
Truist raises ANI Pharmaceuticals target to $65, maintains hold By Investing.com - Investing.com India
Truist Lifts Price Target on ANI Pharmaceuticals to $65 From $62, Keeps Hold Rating - marketscreener.com
ANI Pharmaceuticals, Inc. (ANIP) Soars to 52-Week High, Time to Cash Out? - Yahoo Finance
ANI Pharmaceuticals (ANIP): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
ANI Pharmaceuticals (ANIP): Buy, Sell, Or Hold Post Q4 Earnings? - Barchart.com
Ani Pharmaceuticals Sr. VP sells $27,583 in stock By Investing.com - Investing.com Canada
StockNews.com Downgrades ANI Pharmaceuticals (NASDAQ:ANIP) to Sell - MarketBeat
Deep Dive Into ANI Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) - Benzinga
ANI Pharmaceuticals (ANIP) Set for Potential Earnings Beat - GuruFocus
ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET - GlobeNewswire
ANI Pharmaceuticals Reveals Q1 2025 Earnings Date: Key Executive Insights Coming May 9 - Stock Titan
Zacks.com featured highlights ANI Pharmaceuticals, Expand Energy, Avista Corp and Contango ORE - Yahoo Finance
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Tariff Woes? Play Safe With 4 Low-Beta Stocks: ANIP, EXE, AVA & CTGO - TradingView
ANI Pharmaceuticals at RBC Conference: Strategic Growth in Rare Diseases By Investing.com - Investing.com Canada
Is The Options Market Predicting A Spike In ANI Pharmaceuticals (ANIP) Stock? - Barchart.com
Is the Options Market Predicting a Spike in ANI Pharmaceuticals (ANIP) Stock? - Yahoo Finance
ANI Pharmaceuticals To Present At RBC Capital Markets Conference; Webcast At 7:45 AM ET - Nasdaq
Zacks.com featured highlights include HIS, ANI Pharmaceuticals, Pediatrix Medical, Fresenius Medical Care and LendingTree - Yahoo Finance
ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference - GlobeNewswire
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Fly 25% But Investors Aren't Buying For Growth - simplywall.st
5 Top-Ranked Mid-Cap Stocks to Buy for a Stellar Portfolio - TradingView
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
Should You Buy ANI Pharmaceuticals (ANIP) After Golden Cross? - Zacks Investment Research
Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Alimera Sciences announces change to SmPC allowing all United Kingdom (Great Britain and Northern Ireland) qualified ophthalmic healthcare professionals experienced in intravitreal injections to administer ILUVIEN - PharmiWeb.com
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN
ANI Pharmaceuticals Launches Kionex Suspension For Electrolyte Imbalance Management: Key Trend Transforming... - WhaTech
ANI Pharmaceuticals launches generic Nitazoxanide Tablets By Investing.com - Investing.com South Africa
Ani Pharmaceuticals Launches Nitazoxanide Tablets for Treating Diarrhea -March 19, 2025 at 09:33 am EDT - MarketScreener
ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets - GlobeNewswire
ANI Pharmaceuticals launches generic Nitazoxanide Tablets - Investing.com
ANI Pharmaceuticals Announces The Launch Of Nitazoxanide Tablets -March 19, 2025 at 06:51 am EDT - Marketscreener.com
Generic Drug Alert: ANI Pharmaceuticals Takes On $36M Market With New Alinia Alternative - StockTitan
ANI Pharmaceuticals settles royalty obligation for $17.25 million By Investing.com - Investing.com Australia
ANI Pharmaceuticals Eliminates Royalty Obligation On ILUVIEN And YUTIQ - Nasdaq
ANI Pharmaceuticals settles royalty obligation for $17.25 million - Investing.com India
ANI Pharma buys Iluvien and Yutiq royalties (ANIP:NASDAQ) - Seeking Alpha
ANI Pharma buys royalties linked to Iluvien and Yutiq - MSN
ANI Pharmaceuticals Completes Buyout of Royalty Obligation for Iluvien, Yutiq -March 18, 2025 at 08:20 am EDT - Marketscreener.com
Finanzdaten der Ani Pharmaceuticals Inc-Aktie (ANIP)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
1.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):